Caribou Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CRBU, updated each market day.
CRBU AI Sentiment
AI sees no strong directional signal for Caribou Biosciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Caribou Biosciences, Inc. Common Stock
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Sector
Exchange
Market Cap
$189,408,915
Cap Tier
Employees
97
Headquarters
BERKELEY, CA
Listed Since
July 23, 2021
Website
CRBU Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CRBU Volatility
Caribou Biosciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
